1. Home
  2. MLYS vs FIVN Comparison

MLYS vs FIVN Comparison

Compare MLYS & FIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$25.85

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Logo Five9 Inc.

FIVN

Five9 Inc.

HOLD

Current Price

$34.84

Market Cap

2.4B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLYS
FIVN
Founded
2019
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.4B
IPO Year
2023
2014

Fundamental Metrics

Financial Performance
Metric
MLYS
FIVN
Price
$25.85
$34.84
Analyst Decision
Strong Buy
Buy
Analyst Count
7
18
Target Price
★ $48.67
$26.06
AVG Volume (30 Days)
1.2M
★ 2.0M
Earning Date
05-06-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
37.43
★ 364.71
EPS
N/A
★ 0.25
Revenue
N/A
★ $1,149,088,000.00
Revenue This Year
N/A
$11.39
Revenue Next Year
N/A
$10.00
P/E Ratio
★ N/A
$143.12
Revenue Growth
N/A
★ 10.28
52 Week Low
$22.30
$13.29
52 Week High
$47.65
$40.00

Technical Indicators

Market Signals
Indicator
MLYS
FIVN
Relative Strength Index (RSI) 39.48 53.48
Support Level $22.36 $30.38
Resistance Level $31.36 $34.88
Average True Range (ATR) 1.48 2.07
MACD -0.40 0.11
Stochastic Oscillator 5.09 46.77

Price Performance

Historical Comparison
MLYS
FIVN

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About FIVN Five9 Inc.

Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Intelligent CX platform combines core telephony functionality, omnichannel engagement, and modules into a cloud-based contact-center-as-a-service platform. Five9's modules include digital self-service, agent assist technology, workflow automation, and optimization solutions, as well as artificial intelligence-driven automation solutions that optimize customer service efficiency and manage interaction quality and agent performance.

Share on Social Networks: